Go to interview with Lee S Schwartzberg, MD
Go to interview with Ms B
Go to interview with Karen Dow Meneses, PhD, FAAN, RN
Go to interview with Rowan T Chlebowski, MD, PhD
 
 
 
To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
     
Schwartzberg, MD Lee S Schwartzberg, MD
Medical Director
The West Clinic
Clinical Professor of Medicine
University of Tennessee School of Medicine
Memphis, Tennessee		  
  Click here to download the entire interview  
Track 1 Community-based clinical research
Track 2 Types of clinical trials
Track 3 Role of the Institutional Review Board
Track 4 Funding for clinical trials
Track 5 Access to and availability of clinical trials
Track 6 Utility of the Oncotype DX assay to predict benefit from adjuvant chemotherapy Arrow
Track 7 Use of chemotherapy in patients with node-negative breast cancer Arrow
Track 8 NSABP-B-40: Clinical trial of neoadjuvant chemotherapy with or without bevacizumab Arrow
Track 9 Potential of bevacizumab in the adjuvant and neoadjuvant setting Arrow
Track 10 Implications of bevacizumab-related impaired wound healing Arrow
Track 11 Incidence of hypertension secondary to bevacizumab Arrow
Track 12 Bevacizumab in the treatment of triple-negative breast cancer Arrow
Track 13 Adjuvant docetaxel with cyclophosphamide (TC) Arrow
Track 14 Adjuvant aromatase inhibitors as treatment for postmenopausal patients with hormone receptor-positive breast cancer Arrow
Track 15 Duration of treatment with aromatase inhibitors Arrow
Track 16 Patient adherence to oral therapies Arrow
Track 17 Adoption of trastuzumab in the adjuvant setting Arrow
Track 18 Use of trastuzumab for subcentimeter, node-negative, HER2-positive tumors Arrow
Track 19 Adjuvant docetaxel, carboplatin and trastuzumab (TCH) versus anthracycline-based therapy for HER2-positive breast cancer Arrow
Track 20 Clinical trials evaluating TCH with bevacizumab Arrow
Track 21 Nab paclitaxel in clinical practice Arrow
Track 22 Avoidance of premedications with nab paclitaxel Arrow
     
  Ms B

  
  Click here to download the entire interview  
Track 1 Patient interview: A 50-year-old woman with metastatic disease
Track 2 Impact of the cancer experience on life perspective
Track 3 Patient’s response to the diagnosis of metastatic disease
Track 4 Perspective of a friend on supporting a patient with metastatic breast cancer

 

     
Meneses, RN Karen Dow Meneses, PhD, FAAN, RN
Professor and Associate Dean for Research
School of Nursing, University of Alabama at Birmingham
Birmingham, Alabama
  
  Click here to download the entire interview  
Track 1 Fertility options for younger patients with newly diagnosed breast cancer
Track 2 Gestational carrier as an alternative to pregnancy
Track 3 Premature menopause secondary to systemic therapies
Track 4 Clinical advantage of nab paclitaxel
Track 5 Sleep disturbance and weight gain secondary to corticosteroid use
Track 6 Survivorship issues for patients after completion of primary therapy for breast cancer
Track 7 Factors affecting patient adherence to oral endocrine therapies
Track 8 Patient preference: Oral therapies versus intramuscular injections
Track 9 Patients’ psychosocial bonds with the oncology team members and other patients
Track 10 Addressing survivorship issues with patients after adjuvant therapy
Track 11 Nursing approach for patients experiencing alopecia
     
Chlebowski, MD Rowan T Chlebowski, MD, PhD
Professor of Medicine
David Geffen School of Medicine at UCLA
Chief, Division of Medical Oncology and Hematology
Harbor-UCLA Medical Center
Torrance, California

  
  Click here to download the entire interview  
Track 1 Impact of trastuzumab on risk of recurrence in patients with HER2-positive breast cancer Audio
Track 2 Clinical trials evaluating chemotherapy with trastuzumab in the adjuvant setting
Track 3 Cardiotoxicities associated with chemotherapy in combination with trastuzumab Audio
Track 4 Adjuvant trastuzumab for subcentimeter, node-negative, HER2-positive breast cancer Audio
Track 5 Signs and symptoms of cardiotoxicity in patients receiving trastuzumab Audio
Track 6 Adjuvant therapy for elderly patients with HER2-positive, hormone receptor-negative breast cancer Audio
Track 7 Accuracy of HER2 and hormone receptor testing Audio
Track 8 Adjuvant therapy for hormone receptor-positive, HER2-negative breast cancer
Track 9 TC versus anthracycline-based chemotherapy in the adjuvant setting Audio
Track 10 National guidelines regarding the use of aromatase inhibitors as adjuvant therapy in postmenopausal women Audio
Track 11 Toxicities of tamoxifen versus aromatase inhibitors Audio
Track 12 Optimal duration of adjuvant endocrine therapy Audio
Track 13 Delayed adjuvant endocrine therapy Audio
Track 14 Continuing aromatase inhibitors after five years of therapy
Track 15 Comparison of available aromatase inhibitors

 
Home Terms of Use/Disclaimer | Privacy Policy | Hardware/Software Requirements
Copyright © 2007 Research To Practice, All Rights Reserved		 Contact us